Psoriasis treatment

Current Problems in Dermatology

Volumn 10, Issue 1, 1998, Pages 1-40

  Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PSORALEN;

CLINICAL FEATURE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; MEDICAL DECISION MAKING; PATIENT INFORMATION; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; SKIN DISEASE; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0031915116     PISSN: 10400486     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-0486(98)90003-5     Document Type: Review

References (365)

1. Fleischer AB Jr, Feldman SR, Rapp SR, et al. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol 1996;107:26-9.
2. Koo J. The American Psoriasis Report 1993;1-32.
3. Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of psoriasis. Am J Dermatopathol 1979;1:199-214.
4. Camisa C. Pathogenesis. In: Camisa C, editor. Psoriasis. Cambridge (MA): Blackwell Scientific; 1994. p. 7-21.
5. Weinstein GD. Epidermal cell kinetics. In: Fitzpatrick TB, Eisen AZ, Wolff K, editors. Dermatology in general medicine. New York: McGraw-Hill; 1987. p. 154-65.
6. Griffiths TW, Griffiths CE, Voorhees JJ. Immunopathogenesis and immunotherapy of psoriasis. Dermatol Clin 1995; 13:739-49.
7. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
8. Gottlieb AB. Immunopathogenesis of psoriasis: the road from bench to bedside is a 2-way street. Arch Dermatol 1997;133: 781-2.
9. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96.
10. Fleischer AB Jr, Feldman SR, Bradham DD. Office-based physician services provided by dermatologists in the United States in 1990. J Invest Dermatol 1994;102:93-7.
11. Fleischer AB Jr, Feldman SR, McConnell RC. The most common skin problems seen by family practitioners, 1990-1994. Fam Med 1997;29:648-52.
12. Camisa C. Concurrent diseases, association, and drugs. In: Camisa C, editor. Psoriasis. Cambridge (MA): Blackwell Scientific; 1994. p. 25-39.
13. Gold MH, Holy, Roenigk HH. Beta-blocking drugs and psoriasis: a review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988;19:837-41.
14. Skoven I, Thormann J. Lithium compound treatment and psoriasis. Arch Dermatol 1979;115:1185-7.
15. Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol 1997;2:525-37.
16. Al'Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol 1994;130:199-203.
17. Mazzetti M, Mozzetta A, Soavi GC, et al. Psoriasis, stress and psychiatry: psychodynamic characteristics of Stressors. Acta Derm Venerol 1994;186(Suppl):62-4.
18. Farber EM, Nail L. Psoriasis: a stress-related disease. Cutis 1993;51:322-6.
19. Gupta MA, Schork NJ, Gupta AK, et al. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 1993;28:730-2.
20. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304.
21. Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994;264:1141-5.
22. Elder JT, Nair RP, Voorhees JJ. Epidemiology and the genetics of psoriasis. J Invest Dermatol 1994;102:24S-7S.
23. Wuepper KD, Coulter SN, Haberman A. Psoriasis vulgaris: a genetic approach. J Invest Dermatol 1990;95:2S-4S.
24. Feldman SR, Fleischer AB Jr, Rapp SR, et al. The financial impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564-9.
25. Kent G, al-Abadie M. The psoriasis disability index: further analyses. Clin Exp Dermatol 1993;18:414-6.
26. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
27. Finlay AY, Khan GK, Luscombe DK, et al. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990;123:751-6.
28. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236-44.
29. O'Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. BMJ 1996;313: 919-21.
30. Nichol MB, Margolies JE, Lippa E, et al. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacol Economics 1996;10:644-53.
31. Fleischer AB Jr, Rapp SR, Reboussin DM, et al. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol 1994;102:967-9.
32. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
33. Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996;106:183-6.
34. Farber EM, Raychaudhuri SP. Concept of total care: a third dimension in the treatment of psoriasis. Cutis 1997;59:35-9.
35. Dencker K. Living with psoriasis survey: National Psoriasis Foundation report. Portland (OR): National Psoriasis Foundation; 1993. p. 1-9.
36. Weinstein GD, Krueger JG. An overview of psoriasis. In: Weinstein GD, Gottlieb AB, editors. Therapy of moderate-to-severe psoriasis. Portland (OR): National Psoriasis Foundation; 1993. p. 1-22.
37. Feldman SR. What you can do about managed care? Psoriasis Forum 1996;2:4.
38. National Psoriasis Foundation. Overview of psoriasis treatment. Portland (OR): National Psoriasis Foundation; 1994. p. 1-10.
39. Watsky KL, Freije L, Leneveu MC, et al. Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis 1992;50:383-6.
40. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994;131:673-7.
41. Dodd WA. Tars: their role in the treatment of psoriasis. Dermatol Clin 1993;11:131-5.
42. Williams RE, Tillman DM, White SI, et al. Re-examining crude coal tar treatment for psoriasis. Br J Dermatol 1992;126:608-10.
43. Kar PK, Jha PK, Snehi PS. Evaluation of psoralen with solar ultraviolet light (Puvasol) and adjunctive topical tar therapy in psoriasis. J Indian Med Assoc 1994;92:120-1.
44. Downey DJ, Finlay AY. Combined short contact crude coal tar and dithranol therapy for psoriasis. Clin Exp Dermatol 1986:11:498-501.
45. Silverman A, Menter A, Hairston JL. Tars and anthralins. Dermatol Clin 1995;13:817-33.
46. Kornreich C, Zheng ZS, Xue GZ, et al. A simple method to predict whether topical agents will interfere with phototherapy. Cutis 1996;57:113-8.
47. Clark AR, Feldman SR, Fleischer AB Jr. The safety and efficacy of phototherapy is similar in the elderly and non-elderly. J Geriatr Dermatol 1996;4:1-6.
48. Stem RS. Utilization of outpatient care for psoriasis. J Am Acad Dermatol 1996;35:543-5.
49. Katz HI. Topical corticosteroids. Dermatol Clin 1995;13: 805-15.
50. Liem WH, McCullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 1995;55:306-10.
51. Theeuwes M, Bright R. Use of a hydrocolloid dressing in combination with a topical steroid in plaque psoriasis. Cutis 1996;57:48-50.
52. 1997 Drug Topics Red Book. Montvale (NJ): Medical Economics Company; 1997.
53. McMichael AJ, Griffiths CE, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996; 135:60-4.
54. Lavker RM, Kaidbey K, Leyden JJ. Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid. J Am Acad Dermatol 1992;26:535-44.
55. Walsh P, Aeling JL, Huff L, et al. Hypothalamus-pituitaryadrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993;29:501-3.
56. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991;183:269-74.
57. Griffiths CE, Tranfaglia MG, Kang S. Prolonged occlusion in the treatment of psoriasis: a clinical and immunohistologic study. J Am Acad Dermatol 1995;32:618-22.
58. Kragballe K, Larsen FG. A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta Derm Venereol 1991;71:540-2.
59. Lebwohl M, Abel E, Zanolli M, et al. Topical therapy for psoriasis. Int J Dermatol 1995;34:673-84.
60. Fiore M. Practical aspects of anthralin therapy. Cutis 1990; 46:351-4.
61. Mahrle G, Bonnekoh B, Wevers A, et al. Anthralin: how does it act and are there more favourable derivatives? Acta Derm Venerol 1994;186(Suppl):83-4.
62. Zvulunov A, Anisfeld A, Metzker A. Efficacy of short-contact therapy with dithranol in childhood psoriasis. Int J Dermatol 1994;33:808-10.
63. Walker GB, Harrison PV, Seville RH, et al. Short contact dithranol therapy: advantages of a stiff emulsifying ointment base. Br J Dermatol 1989;120:277-83.
64. Kingston TP, Lowe NJ, Whitefield M, et al. Short-contact anthralin therapy for psoriasis using an aqueous cream formulation. Cutis 1987;39:155-7.
65. Brandt H, Gordin A, Mustakallio KK. Ambulatory treatment of psoriasis with dithranol sticks: a novel paraffin formulation. Dermatologica 1985;171:459-62.
66. Burden AD, Muston H, Beck MH. Intolerance and contact allergy to tar and dithranol in psoriasis. Contact Dermatitis 1994;31:185-6.
67. Van de Kerkhof PC, Timmerman MG. The effect of clobetasol-17-propionate and crude coal tar on dithranol-induced inflammation: a clinical and biochemical study. Acta Derm Venerol 1990;70:434-7.
68. Ramsay B, Lawrence CM, Shuster S, et al. Reduction of anthralin-induced inflammation by application of amines. J Am Acad Dermatol 1990;22:765-72.
69. Ramsay B, Lawrence CM, Bruce JM, et al. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 1990; 23:73-6.
70. de Mare S, Calis N, den Hartog G, et al. Outpatient treatment with short-contact dithranol: the impact of frequent concentration adjustments. Acta Derm Venerol 1989;69:449-51.
71. MacDonald KJ, Marks J. Short contact anthralin in the treatment of psoriasis: a study of different contact times. Br J Dermatol 1986;114:235-9.
72. Jones SK, Campbell WC, Mackie RM. Out-patient treatment of psoriasis: short contact and overnight dithranol therapy compared. Br J Dermatol 1985;113:331-7.
73. Kneczke M, Rahm C, Landersjo L. The influence of salicylic acid on the in vitro release of anthralin from an o/w cream. Acta Pharm Nordica 1990;2:313-8.
74. Weller PJ, Newman CM, Middleton KR, et al. Stability of a novel dithranol ointment formulation, containing ascorbyl palmitate as an anti-oxidant. J Clin Pharm Ther 1990;15:419-23.
75. Green PG, Kennedy CT, Forbes DR. Anthralin stability in various vehicles. J Am Acad Dermatol 1987;16:984-8.
76. Wang JC, Krazmien RJ, Dahlheim CE, et al. Anthralin stain removal. J Am Acad Dermatol 1986;15:951-5.
77. Van der Vleuten CJ, Gerritsen MJ, De Jong EM, et al. A novel dithranol formulation (Micanol): the effects of monotherapy and UVB combination therapy on epidermal differentiation, proliferation and cutaneous inflammation in psoriasis vulgaris. Acta Derm Venerol 1996;76:387-91.
78. Lindahl A. Embedding of dithranol in lipid crystals. Acta Derm Venerol 1992;172(Suppl):13-6.
79. Christensen OB, Brolund L. Clinical studies with a novel dithranol formulation (Micanol) in combination with UVB at day-care centres. Acta Derm Venerol 1992;172(Suppl):17-9.
80. Kragballe K, Iversen L. Calcipotriol: a new topical antipsoriatic. Dermatol Clin 1993;11:137-41.
81. Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol 1992;27:1001-8.
82. Berth-Jones J, Fletcher A, Hutchinson PE. Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol and betamethasone valerate. Br J Dermatol 1992;126:356-61.
83. Cagnoni ML, Ghersetich I, Lotti T, et al. Treatment of psoriasis vulgaris with topical calcipotriol: is the clinical improvement of lesional skin related to a down-regulation of some cell adhesion molecules? Acta Derm Venerol 1994;186 (Suppl): 55-7.
84. Palleschi GM, Gentili A, Caproni M, et al. Structural alterations of basal keratinocytes and capillary loop in psoriasis during treatment with topical calcipotriol. Acta Derm Venerol 1994;186(Suppl):49-51.
85. Van der Vleuten CJ, De Jong EM, Van de Kerkhof PC. Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res 1996; 288:366-72.
86. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994;31:755-9.
87. Berardesca E, Vignoli GP, Farinelli N, et al. Non-invasive evaluation of topical calcipotriol versus clobetasol in the treatment of psoriasis. Acta Derm Venerol 1994;74:302-4.
88. Dubertret L, Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: a randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992;27:983-8.
89. Pariser DM, Pariser RJ, Breneman D, et al. Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study. Arch Dermatol 1996; 132:1527.
90. Berth-Jones J, Chu AC, Dodd WA, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992:127:266-71.
91. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736-43.
92. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-6.
93. Ramsay CA, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994;189:260-4.
94. Cullen SI. Long-term effectiveness and safety of topical calcipotriene for psoriasis: Calcipotriene Study Group. South Med J 1996;89:1053-6.
95. Oranje AP, Marcoux D, Svensson A, et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997; 36:203-8.
96. Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol 1996;135:390-3.
97. Gray JD, Bottomley W, Layton AM, et al. The use of calcipotriol in HIV-related psoriasis. Clin Exp Dermatol 1992;17:342-3.
98. Bourke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol 1993;18:504-6.
99. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268-9.
100. Bourke JF, Berth-Jones J, Iqbal SJ, et al. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 1993;129:74-6.
101. Mortensen L, Kragballe K, Wegmann E, et al. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism: a randomized, double-blind, placebo-controlled study. Acta Derm Venerol 1993;73: 300-4.
102. Guzzo C, Lazarus G, Goffe BS, et al. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. J Am Acad Dermatol 1996;34:429-33.
103. Lidbrink P, Johannesson A, Hammar H. Psoriasis treatment: faster clearance when UVB-dithranol is combined with topical clobetasol propionate. Dermatologica 1986;172:164-8.
104. Meola T Jr, Soter NA, Lim HW. Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature. Arch Dermatol 1991;127:1708-13.
105. Kokelj F, Lavaroni G, Guadagnini A. UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris. Acta Derm Venerol 1995;75:386-7.
106. Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994;130:79-82.
107. Bagot M, Grossman R, Pamphile R, et al. Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis. Comptes Rendus Acad Sci - Serie Iii, Sci Vie 1994;317:282-6.
108. Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994;31: 68-74.
109. McKenna KE, Stern RS. Photosensitivity associated with combined UV-B and calcipotriene therapy [see comments]. Arch Dermatol 1995;131:1305-7.
110. Lebwohl M, Hecker D, Martinez J, et al. Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol 1997; 37:93-5.
111. Molin L, Cutler TP, Helander I, et al. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis: a randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 1997;136:89-93.
112. Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994;131:678-83.
113. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483-7.
114. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994;30:581-90.
115. Weinstein GD. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol 1996;135(Suppl 49):32-6.
116. Marks R. Early clinical development of tazarotene. Br J Dermatol 1996;135(Suppl 49):26-31.
117. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92.
118. Chandraratna RA. Tazarotene: first of a new generation of receptor-selective retinoids. Br J Dermatol 1996;135(Suppl 49):18-25.
119. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
120. Mangelsdorf DJ, Kliewer SA, Kakizuka A, et al. Retinoid receptors. Recent Prog Horm Res 1993;48:99-121.
121. Brinkmann AO. Steroid hormone receptors: activators of gene transcription. J Pediatr Endocrinol Metab 1994;7:275-82.
122. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86.
123. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995;83:851-7.
124. Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992;68:397-406.
125. Mangelsdorf DJ. Vitamin A receptors. Nutr Rev 1994;52: S32-44.
126. 3 signalling. Nature 1992;355: 446-9.
127. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-50.
128. Lew-Kaya DA, Lue JC, Sefton J, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. Proceedings of the annual meeting of the American Academy of Dermatology; 1997 Mar 21-26; San Francisco, California. San Francisco: The Academy; 1997.
129. Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991;24:443-7.
130. Wright S, Mann RJ. Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate) with coal tar pomade in the treatment of scalp psoriasis. Clin Exp Dermatol 1985;10:375-8.
131. Helm TN, Camisa C. Psoriasis of the scalp. In: Camisa C, editor. Psoriasis. Cambridge (MA): Blackwell Scientific; 1994. p. 85-96.
132. Lindelof B, Johannesson A. Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays: a comparative randomized trial. Br J Dermatol 1988;119: 241-4.
133. De Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996;193:300-3.
134. Layton AM, Sheehan-Dare R, Cunliffe WJ. A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. Br J Dermatol 1991;124:581-4.
135. De Rie MA, Van Eendenburg JP, Versnick AC, et al. A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema. Br J Dermatol 1995;132:964-9.
136. Reitamo S, Erkko P, Remitz A, et al. Cyclosporine in the treatment of palmoplantar pustulosis: a randomized, double-blind, placebo-controlled study [see comments]. Arch Dermatol 1993;129:1273-9.
137. Reitamo S, Erkko P, Remitz A. Cyclosporin for palmoplantar pustulosis. J Autoimmun 1992;5(Suppl A):285-7.
138. Camisa C. Variants of psoriasis. In: Camisa C, editor. Psoriasis. Cambridge (MA): Blackwell Scientific; 1994. p. 53-83.
139. Lindelof B, Beitner H. The effect of grenz ray therapy on pustulosis palmoplantaris: a double-blind bilateral trial. Acta Derm Venerol 1990;70:529-31.
140. Kienbaum S, Lehmann P, Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 1996; 135:647-50.
141. Parrish JA. Phototherapy of psoriasis with UVB. Acta Derm Venereol 1984;112(Suppl):25-7.
142. Koo J. The art of UVB phototherapy for the treatment of psoriasis. In: Weinstein GD, Gottlieb AB, editors. Therapy of moderate-to-severe psoriasis. Portland (OR): National Psoriasis Foundation; 1993. p. 56-74.
143. Parrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1981;76:359-62.
144. Diffey BL. Ultraviolet radiation physics and the skin. Phys Med Biol 1980;25:405-26.
145. Voorhees JJ. Dohi memorial lecture. Psoriasis: an immunological disease. J Dermatol 1996;23:851-7.
146. Camisa C. UVB phototherapy and coal tar. In: Camisa C, editor. Psoriasis. Cambridge (MA): Blackwell Scientific; 1994. p. 205-26.
147. Parrish JA. Ultraviolet phototherapy of psoriasis. Pharmacol Ther 1981;15:313-20.
148. Adrian RM, Parrish JA, Momtaz-T K, et al. Outpatient phototherapy for psoriasis. Arch Dermatol 1981;117:623-6.
149. LeVine MJ, Parrish JA. Outpatient phototherapy of psoriasis. Arch Dermatol 1980;116:552-4.
150. Picot E, Meunier L, Picot-Debeze MC, et al. Treatment of psoriasis with a 311-nm UVB lamp. Br J Dermatol 1992;127: 509-12.
151. Storbeck K, Holzle E, Schurer N, et al. Narrow-band UVB (311 nm) versus conventional broad-band UVB with and without dithranol in phototherapy for psoriasis. J Am Acad Dermatol 1993;28:227-31.
152. Oakley AM, Wyllie K. A review of ultraviolet treatment for psoriasis at Waikato Hospital. Aust J Dermatol 1996;37:132-6.
153. Studniberg HM, Weller P. PUVA, UVB, psoriasis, and non-melanoma skin cancer. J Am Acad Dermatol 1993;29: 1013-22.
154. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up study. Cancer 1994;73:2759-64.
155. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1980;1:732-5.
156. Horwitz SN, Johnson RA, Sefton J, et al. Addition of a topically applied corticosteroid to a modified Goeckerman regimen for treatment of psoriasis: effect on duration of remission. J Am Acad Dermatol 1985;13:784-91.
157. Armstrong RB, Leach EE, Fleiss JL, et al. Modified Goeckerman therapy for psoriasis: a two-year follow-up of a combined hospital-ambulatory care program. Arch Dermatol 1984;120:313-8.
158. Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol 1983;9:59-65.
159. Cort DH, Schleider NR, Moskowitz RS, et al. Retrospective analysis of a modified Goeckerman regimen for the treatment of psoriasis. Cutis 1978;25:201-3.
160. Muller SA, Perry HO. The Goeckerman treatment in psoriasis: six decades of experience at the Mayo Clinic. Cutis 1985;34:265-8.
161. Le Vine MJ, White HA, Parrish JA. Components of the Goeckerman regimen. J Invest Dermatol 1979;73:170-3.
162. Belsito DV, Kechijian P. The role of tar in Goeckerman therapy. Arch Dermatol 1982;118:319-21.
163. Petrozzi JW, Barton JO, Kaidbey KK, et al. Updating the Goeckerman regimen for psoriasis. Br J Dermatol 1978;98: 437-44.
164. Marsico AR, Eaglstein WH, Weinstein GD. Ultraviolet light and tar in the Goeckerman treatment of psoriasis. Arch Dermatol 1976;112:1249-50.
165. Harber LC, Armstrong RB, Leach EE, et al. Preliminary report: modified Goeckerman therapy for hospitalized patients: ambulatory day care center and improved quantitative dosimetry. J Invest Dermatol 1981;77:162-6.
166. Pittelkow MR, Perry HO, Muller SA, et al. Skin cancer in patients with psoriasis treated with coal tar: a 25-year follow-up study. Arch Dermatol 1981;117:465-8.
167. Sander HM, Morris LF, Phillips CM, et al. The annual cost of psoriasis. J Am Acad Dermatol 1993;28:422-5.
168. Swinehart JM, Lowe NJ. UVABA therapy for psoriasis: efficacy with shortened treatment times with the combined use of coal tar, anthralin, and metal halide ultraviolet machines. J Am Acad Dermatol 1991;24:594-7.
169. Boer J, Smeenk G. Effect of short-contact anthralin therapy on ultraviolet B irradiation of psoriasis. J Am Acad Dermatol 1986;15:198-204.
170. Lebwohl M, Berman B, France DS. Addition of short-contact anthralin therapy to an ultraviolet B phototherapy regimen: assessment of efficacy. J Am Acad Dermatol 1985;13: 780-4.
171. Schulze HJ, Schauder S, Mahrle G, et al. Combined tar-anthralin versus anthralin treatment lowers irritancy with unchanged antipsoriatic efficacy: modifications of short-contact therapy and Ingram therapy. J Am Acad Dermatol 1987; 17:19-24.
172. Ryatt KS, Statham BN, Rowell NR. Short-contact modification of the Ingram regime. Br J Dermatol 1984;111:455-9.
173. Statham BN, Ryatt KS, Rowell NR. Short-contact dithranol therapy: a comparison with the Ingram regime. Br J Dermatol 1984;110:703-8.
174. Zalla MJ, Muller SA. The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Derm Venereol 1996;195(Suppl):1-15.
175. Lindgren S, Groth O. Generalized pustular psoriasis: a report on thirteen patients. Acta Derm Venereol 1976;56: 139-47.
176. Picascia DD, Garden JM, Freinkel RK, et al. Treatment of resistant severe psoriasis with systemic cyclosporine. J Am Acad Dermatol 1987;17:408-14.
177. Jordan WP Jr, Clarke AM, Hale RK. Long-term modified Goeckerman regimen for psoriasis using an ultraviolet B light source in the home. J Am Acad Dermatol 1981;4:584-91.
178. Stern RS, Armstrong RB, Anderson TF, et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. J Am Acad Dermatol 1986;15:546-52.
179. Camisa C. Psoriasis. Oxford: Blackwell Scientific Publications; 1994. p. 218.
180. Feldman SR, Clark A, Reboussin DM, et al. An assessment of potential problems of home phototherapy treatment of psoriasis. Cutis 1996;58:71-3.
181. Lowe NJ. Home ultraviolet phototherapy. Semin Dermatol 1992;11:284-6.
182. Lowe NJ. Managing your psoriasis. New York: Mastermedia Limited; 1993. p. 59.
183. National Psoriasis Foundation. Home phototherapy. Portland (OR): National Psoriasis Foundation; 1993.
184. Parrish JA. Treatment of psoriasis with long-wave ultraviolet light. Arch Dermatol 1977;113:1525-8.
185. Fleischer AB Jr, Feldman SR, Clark AR, et al. An uncontrolled trial of commercial tanning bed treatments for psoriasis. J Invest Dermatol. In press.
186. Fleischer AB Jr, Feldman SR, Rapp SR, et al. Alternative therapies commonly used within a population of patients with psoriasis. Cutis 1996;58:216-20.
187. Woman dies from burns. Winston-Salem Journal 1989;C20.
188. Helm TN, Camisa C. Psoralens and photochemotherapy (PUVA). In: Camisa C, editor. Psoriasis. Cambridge (MA): Blackwell Scientific; 1994. p. 227-61.
189. Parrish JA, Fitzpatrick TB, Tanenbaum L, et al. Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. N Engl J Med 1974;291:1207-11.
190. Melski JW, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977;68: 328-35.
191. Vallat VP, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994;180:283-96.
192. Morison WL. PUVA therapy. In: Weinstein GD, Gottlieb AB, editors. Therapy of moderate-to-severe psoriasis. Portland (OR): National Psoriasis Foundation; 1993. p. 23-38.
193. Sakuntabhai A, Sharpe GR, Farr PM. Response of psoriasis to twice weekly PUVA. Br J Dermatol 1993;128:166-71.
194. Fischer T. PUVA: how to use it for maintenance. Semin Dermatol 1992;11:287-90.
195. Sakuntabhai A, Diffey BL, Farr PM. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment. Br J Dermatol 1995;133:919-23.
196. Bonnot D, Beani JC, Boitard M, et al. Determination of 8-methoxypsoralen kinetics: a relevant factor in the treatment of psoriasis by psoralen plus ultraviolet A therapy. Photoderm Photoimmun Photomed 1994;10:33-7.
197. Collins P, Wainwright NJ, Amorim I, et al. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol 1996;135: 248-54.
198. Calzavara-Pinton PG, Ortel B, Honigsmann H, et al. Safety and effectiveness of an aggressive and individualized bath: PUVA regimen in the treatment of psoriasis. Dermatology 1994;189:256-9.
199. Collins P, Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 1992;127:392-5.
200. Hallman CP, Koo JY, Omohundro C, et al. Plasma levels of 8-methoxypsoralen after topical paint PUVA on nonpalmoplantar psoriatic skin. J Am Acad Dermatol 1994;31:273-5.
201. Pai S, Srinivas CR. Bathing suit delivery of 8-methoxypsoralen for psoriasis: a double-blind, placebo-controlled study. Int J Dermatol 1994;33:576-8.
202. Streit V, Wiedow O, Christophers E. Treatment of psoriasis with polyethylene sheet bath PUVA. J Am Acad Dermatol 1996;35:208-10.
203. Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 1991;127:347-50.
204. Calzavara-Pinton PG, Carlino A, Manfredi E, et al. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol 1994;186(Suppl):164-5.
205. Brazzelli V, Borroni G, Berardesca E, et al. PUVA-treated psoriatic skin as a model for cutaneous wrinkling assessed by skin replicas. Acta Derm Venereol 1994; 186(Suppl): 162-3.
206. Wolff K. Side-effects of psoralen photochemotherapy (PUVA). Br J Dermatol 1990;122(Suppl 36):117-25.
207. Sips AJ, Netelenbos JC, Barto R, et al. Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis. J Am Acad Dermatol 1994;30:966-9.
208. Maier H, Schemper M, Ortel B, et al. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. Dermatology 1996;193:185-91.
209. McKenna KE, Patterson CC, Handley J, et al. Cutaneous neoplasia following PUVA therapy for psoriasis. Br J Dermatol 1996;134:639-42.
210. Kanerva L, Lauharanta J. PUVA: lentigo. Photo-Dermatology 1985;2:49-51.
211. Rhodes AR, Stern RS, Melski JW. The PUVA lentigo: an analysis of predisposing factors. J Invest Dermatol 1983;81: 459-63.
212. Takashima A, Sunohara A, Matsunami E, et al. Comparison of therapeutic efficacy of topical PUVA, oral etretinate, and combined PUVA and etretinate for the treatment of psoriasis and development of PUVA lentigines and antinuclear antibodies. J Dermatol 1988;15:473-9.
213. Cox NH, Jones SK, Downey DJ, et al. Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study. Br J Dermatol 1987;116:145-52.
214. Kietzmann H, Christophers E. Pigmentary lesions after PUVA treatment. Dermatologica 1984;168:306-8.
215. Abel EA, Reid H, Wood C, et al. PUVA-induced melanocytic atypia: Is it confined to PUVA lentigines? J Am Acad Dermatol 1985;13:761-8.
216. Ros AM, Wennersten G, Lagerholm B. Long-term photochemotherapy for psoriasis: a histopathological and clinical follow-up study with special emphasis on tumour incidence and behavior of pigmented lesions. Acta Derm Venereol 1983;63:215-21.
217. Rhodes AR, Harrist TJ, Momtaz T-K. The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. J Am Acad Dermatol 1983;9:47-58.
218. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997;336: 1041-5.
219. Stern RS, Vakeva LH. Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. J Invest Dermatol 1997; 108:897-900.
220. Ehmann CW, Voorhees JJ. International studies of the efficacy of etretinate in the treatment of psoriasis. J Am Acad Dermatol 1982;6:692-6.
221. Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol 1987;16:267-91.
222. Gollnick HP. Oral retinoids: efficacy and toxicity in psoriasis. Br J Dermatol 1996;135(Suppl 49):6-17.
223. Kaplan RP, Russell DH, Lowe NJ. Etretinate therapy for psoriasis: clinical responses, remission times, epidermal DNA and polyamine responses. J Am Acad Dermatol 1983;8: 95-102.
224. Wolska H, Jablonska S, Bounameaux Y. Etretinate in severe psoriasis: results of double-blind study and maintenance therapy in pustular psoriasis. J Am Acad Dermatol 1983;9: 883-9.
225. Wolska H, Jablonska S, Langner A, et al. Etretinate therapy in generalized pustular psoriasis (Zumbusch type). Immediate and long-term results. Dermatologica 1985;171:297-304.
226. Baker H. Generalized pustular psoriasis. In: Farber EM, Cox AJ, editors. Psoriasis: proceedings of the International Symposium, Stanford University, 1971. Stanford (CA): Stanford University Press; 1971. p. 69-77.
227. White SI, Marks JM, Shuster S. Etretinate in pustular psoriasis of palms and soles. Br J Dermatol 1985;113:581-5.
228. Matsunami E, Takashima A, Mizuno N, et al. Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections. J Dermatol 1990;17:92-6.
229. Slawsky LD, Libow LF. Successful treatment of acrodermatitis continua of Hallopeau with etretinate. J Am Acad Dermatol 1990;23:1176-8.
230. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988;119:755-9.
231. White SI, Puttick L, Marks JM. Low-dose etretinate in the maintenance of remission of palmoplantar pustular psoriasis. Br J Dermatol 1986;115:577-82.
232. Pearson LH, Allen BS, Smith JG Jr. Acrodermatitis continua of Hallopeau: treatment with etretinate and review of relapsing pustular eruptions of the hands and feet. J Am Acad Dermatol 1984;11:755-62.
233. Foged E, Holm P, Larsen PO, et al. A randomized trial of etretinate (Tigason) in palmoplantar pustulosis. Dermatologica 1983;166:220-3.
234. Tanew A, Guggenbichler A, Honigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682-4.
235. Perkins W, Williams RE, Vestey JP, et al. A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis. Br J Dermatol 1993;129:584-9.
236. Ortel B, Perl S, Kinaciyan T, et al. Comparison of narrowband (311 nm) UVB and broad-band UVA after oral or bath-water 8-methoxypsoralen in the treatment of psoriasis. J Am Acad Dermatol 1993;29:736-40.
237. Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988;177:218-24.
238. Rosen K, Mobacken H, Swanbeck G. PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris: a placebo-controlled comparative trial. Arch Dermatol 1987;123: 885-9.
239. Lawrence CM, Marks J, Parker S, et al. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. Br J Dermatol 1984;110:221-6.
240. Berth-Jones J, Shuttleworth D, Hutchinson PE. A study of etretinate alopecia. Br J Dermatol 1990;122:751-5.
241. Ishida Y, Ozawa A, Ohkido M, et al. Joint pains with psoriasis and long-term systemic etretinate therapy: a case report and summary of 12 cases. J Dermatol 1993;20:651-3.
242. Archer CB, Elias PM, Lowe NJ, et al. Extensive spinal hyperostosis in a patient receiving isotretinoin: progression after 4 years of etretinate therapy. Clin Exp Dermatol 1989;14: 319-21.
243. Halkier-Sorensen L, Andresen J. A retrospective study of bone changes in adults treated with etretinate. J Am Acad Dermatol 1989;20:83-7.
244. Okada N, Nomura M, Morimoto S, et al. Bone mineral density of the lumbar spine in psoriatic patients with long term etretinate therapy. J Dermatol 1994;21:308-11.
245. DiGiovanna JJ, Sollitto RB, Abangan DL, et al. Osteoporosis is a toxic effect of long-term etretinate therapy [see comments]. Arch Dermatol 1995;131:1263-7.
246. Thirumoorthy T, Shupack JL. Adverse hepatic reactions associated with etretinate in patients with psoriasis: analysis of 22 cases. Ann Acad Med Singapore 1988;17:477-81.
247. Camuto P, Shupack J, Orbuch P, et al. Long-term effects of etretinate on the liver in psoriasis. Am J Surg Pathol 1987;11: 30-7.
248. Weiss VC, West DP, Ackerman R, et al. Hepatotoxic reactions in a patient treated with etretinate. Arch Dermatol 1984;120:104-6.
249. Grossman RM, Delaney RJ, Brinton EA, et al. Hyper-triglyceridemia in patients with psoriasis treated with cyclosporine [see comments]. J Am Acad Dermatol 1991;25: 648-51.
250. Stern RS, Fitzgerald E, Ellis CN, et al. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995;33:44-52.
251. Hammer CJ 3d, Carter CC, Hanifin JM. Peripheral neuropathy during etretinate therapy for psoriasis. J Am Acad Dermatol 1993;28:272-3.
252. Henderson CA, Highet AS. Depression induced by etretinate. BMJ 1989;298:964.
253. Albin RL, Silverman AK, Ellis CN, et al. A new syndrome of axial muscle rigidity associated with etretinate therapy. Mov Disord 1988;3:70-6.
254. Hodak E, David M, Gadoth N, et al. Etretinate-induced skeletal muscle damage. Br J Dermatol 1987;116:623-6.
255. Cribier B, Welsch M, Heid E. Renal impairment probably induced by etretinate. Dermatology 1992;185:266-8.
256. Cunningham WJ, Geiger JM. Practical use of retinoids in psoriasis. Semin Dermatol 1992;11:291-301.
257. Lowe NJ, Prystowsky JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24: 591-4.
258. Bleiker TO, Bourke JF, Graham-Brown RA, et al. Etretinate may work where acitretin fails. Br J Dermatol 1997;136: 368-70.
259. Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis: results of a Nordic multicentre study. Acta Derm Venereol 1989;69:35-40.
260. Talme T, Lund-Rosell B, Sundquist KG, et al. Peptide T: a new treatment for psoriasis? A review of our experiences. Acta Derm Venereol 1994;186(Suppl):76-8.
261. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994;189: 109-16.
262. Chou RC, Wyss R, Huselton CA, et al. A potentially new metabolic pathway: ethylesterification of acitretin. Xenobiotica 1992;22:993-6.
263. Paige DG, Judge MR, Shaw DG, et al. Bone changes and their significance in children with ichthyosis on long-term etretinate therapy. Br J Dermatol 1992;127:387-91.
264. Gilbert M, Ellis CN, Voorhees JJ. Lack of skeletal radiographic changes during short-term etretinate therapy for psoriasis. Dermatologica 1986;172:160-3.
265. Lowe NJ. Systemic retinoid therapy. In: Weinstein GD, Gottlieb AB, editors. Therapy of moderate-to-severe psoriasis. Portland (OR): National Psoriasis Foundation; 1993. p. 94-105.
266. Jeffes EW III, Weinstein GD. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin 1995;13:875-90.
267. Collins P, Rogers S. The efficacy of methotrexate in psoriasis: a review of 40 cases. Clin Exp Dermatol 1992;17:257-60.
268. Bjerring P, Beck HI, Zachariae H, et al. Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study. Acta Derm Venereol 1986;66:515-9.
269. Zanolli MD, Sherertz EF, Hedberg AE. Methotrexate: anti-inflammatory or antiproliferative? J Am Acad Dermatol 1997;22:523-4.
270. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
271. Rees RB. Methotrexate for psoriasis: 1981. Cutis 1981;28: 166-8.
272. Ashton RE, Millward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982;79:229-32.
273. Bergstresser PR, Schreiber SH, Weinstein GD. Systemic chemotherapy for psoriasis: a national survey. Arch Dermatol 1976;112:977-81.
274. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993;28:466-9.
275. Hills RJ, Ive FA. Folinic acid rescue used routinely in psoriatic patients with known methotrexate "sensitivity." Acta Derm Venereol 1992;72:438-40.
276. Shupack JL, Webster GF. Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA 1988;259: 3594-6.
277. Mayall B, Poggi G, Parkin JD. Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. Med J Aust 1991;155:480-4.
278. Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 1987;17:1055-6.
279. Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol 1996;35: 835-8.
280. Kaplan DL, Olsen EA. Erosion of psoriatic plaques after chronic methotrexate administration. Int J Dermatol 1988;27: 59-62.
281. Tung JP, Maibach HI. The practical use of methotrexate in psoriasis. Drags 1990;40:697-712.
282. Morris LF, Harrod MJ, Menter MA, et al. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993;29:913-6.
283. Schwartz GF, Anderson ST. Methotrexate induced pneumonitis in a young woman with psoriasis and rheumatoid arthritis. J Rheumatol 1990;17:980.
284. Cottin V, Tebib J, Massonnet B, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996;109:933-8.
285. Zonneveld IM, Bakker WK, Dijkstra PF, et al. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996;132: 184-7.
286. Roenigk HH Jr, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988;19:145-56.
287. Themido R, Loureiro M, Pecegueiro M, et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992;72:361-4.
288. McHenry PM, Bingham EA, Callender ME, et al. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity. Br J Dermatol 1992;127:122-5.
289. Oogarah PK, Rowland PL, Mitchell DM, et al. Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes. Br J Dermatol 1995;133:512-8.
290. O'Connor GT, Olmstead EM, Zug K, et al. Detection of hepatotoxicity associated with methotrexate therapy for psoriasis. Arch Dermatol 1989;125:1209-17.
291. Gilbert SC, Klintmalm G, Menter A, et al. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis: a word of caution in light of the expanding use of this 'steroid-sparing' agent. Arch Intern Med 1990;150:889-91.
292. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment: improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989;125:1218-24.
293. Boffa MJ, Chalmers RJ, Haboubi NY, et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995;133:774-8.
294. Lanse SB, Arnold GL, Gowans JD, et al. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: an acceptable risk/benefit ratio. Digest Dis Sci 1985;30:104-9.
295. Dolan OM, Burrows D, Irvine A, et al. The value of a base-line liver biopsy prior to methotrexate treatment. Br J Dermatol 1994;131:891-4.
296. Van Dooren-Greebe RJ, Kuijpers AL, Termorshuizen F, et al. Interruption of long-term methotrexate treatment in psoriasis: evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate. Acta Derm Venereol 1995;75:393-6.
297. Kumar B, Handa S, Kaur I. Short term methotrexate therapy in psoriasis. Indian J Med Res 1994;100:277-80.
298. Clark AR, Feldman SR. Intermittent, short term use of methotrexate for exacerbations of psoriasis. Int J Dermatol. In press.
299. Moschella SL. Chemotherapy of psoriasis: ten years of experience. Int J Dermatol 1976;15:373-8.
300. Zackheim HS, Glogau RG, Fisher DA, et al. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994;30:452-8.
301. Leavell UW Jr, Yarbro JW. Hydroxyurea: a new treatment for psoriasis. Arch Dermatol 1970;102:144-50.
302. Rosten M. Hydroxyurea: a new antimetabolite in the treatment of psoriasis. Br J Dermatol 1971;85:177-81.
303. Moschella SL, Greenwald MA. Psoriasis with hydroxyurea: an 18-month study of 60 patients. Arch Dermatol 1973;107: 363-8.
304. Roe LD, Wilson JW. Hydroxyurea therapy. Arch Dermatol 1973;108:426-7.
305. Leavell UW Jr, Mersack IP, Smith C. Survey of the treatment of psoriasis with hydroxyurea. Arch Dermatol 1973;107:467.
306. Boyd AS, Neldner KH. Hydroxyurea therapy. J Am Acad Dermatol 1991;25:518-24.
307. Layton AM, Sheehan-Dare RA, Goodfield MJ, et al. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989;121:647-53.
308. Dahl MG, Comaish JS. Long-term effects of hydroxyurea in psoriases. BMJ 1972;4:585-7.
309. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256: 3110-6.
310. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991;324:277-84.
311. Ellis CN. Cyclosporine in the treatment of severe psoriasis. In: Weinstein GD, Gottlieb AB, editors. Therapy of moderate-to-severe psoriasis. Portland (OR): National Psoriasis Foundation; 1993. p. 106-24.
312. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of Cyclosporine in the treatment of psoriasis [see comments]. Arch Dermatol 1996;132:623-9.
313. Georgala S, Rigopoulos D, Aroni K, et al. Generalized pustular psoriasis precipitated by topical calcipotriol cream. Int J Dermatol 1994;33:515-6.
314. Mahrle G, Schulze HJ, Farber L, et al. Low-dose short-term Cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32:78-88.
315. Christophers E, Mrowietz U, Henneicke HH, et al. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol 1992;26:86-90.
316. Araugo OE, Flowers FP, Brown K. Vitamin D therapy in psoriasis. DICP 1991;25:835-9.
317. Lowe NJ, Wieder JM, Rosenbach A, et al. Long-term low-dose Cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996;35: 710-9.
318. Ellis CN, Fradin MS, Hamilton TA, et al. Duration of remission during maintenance cyclosporine therapy for psoriasis: relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995;131: 791-5.
319. Mrowietz U, Farber L, Henneicke-von Zepelin HH, et al. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. J Am Acad Dermatol 1995;33:470-5.
320. Shupack J, Abel E, Bauer E, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997;36:423-32.
321. Burns MK, Ellis CN, Eisen D, et al. Intralesional cyclosporine for psoriasis: relationship of dose, tissue levels, and efficacy. Arch Dermatol 1992;128:786-90.
322. Ho VC, Griffiths CE, Ellis CN, et al. Intralesional cyclosporine in the treatment of psoriasis: a clinical, immunologic, and pharmacokinetic study. J Am Acad Dermatol 1990;22:94-100.
323. Taniguchi S, Kobayashi H, Ishii M. Treatment of psoriasis by cyclosporine and grapefruit juice. Arch Dermatol 1996;132:1249.
324. Stiller MJ, Pak GH, Kenny C, et al. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis: an assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol 1992;27:434-8.
325. Messana JM, Rocher LL, Ellis CN, et al. Effects of cyclosporine on renal function in psoriasis patients. J Am Acad Dermatol 1990;23:1288-91.
326. Margolis DJ, Guzzo C, Johnson J, et al. Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day. J Am Acad Dermatol 1992;26:195-7.
327. Pei Y, Scholey JW, Katz A, et al. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kidney Dis 1994;23:528-36.
328. Koo JY, Kadonaga JN, Wintroub BV, et al. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992;26:836-40.
329. Gilbert SC, Emmett M, Menter A, et al. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. J Am Acad Dermatol 1989;21:470-4.
330. Silverman AK, Emmett M, Menter A. Can maintenance cyclosporine be used in psoriasis without decreasing renal function? Semin Dermatol 1992;11:302-12.
331. Jegasothy BV, Ackerman CD, Todo S, et al. Tacrolimus (FK 506): a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992;128:781-5.
332. Anonymous. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study: the European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol 1996;132:419-23.
333. Lemster BH, Carroll PB, Rilo HR, et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 1995;99: 148-54.
334. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 1996;153: 85-106.
335. Chambers CA, Krummel MF, Boitel B, et al. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 1996;153:27-46.
336. Ranger AM, Das MP, Kuchroo VK, et al. B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int Immunol 1996;8:1549-60.
337. Nakakura EK, Shorthouse RA, Zheng B, et al. Long-term survival of solid organ allografts by brief anti-lymphocyte function - associated antigen-1 monoclonal antibody monotherapy. Transplantation 1996;62:547-52.
338. Willenborg DO, Staykova MA, Miyasaka M. Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol 1996;157:1973-80.
339. Gordon EJ, Myers KJ, Dougherty JP, et al. Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 1995;62:153-60.
340. Camisa C. Miscellaneous treatments. In: Anonymous. Psoriasis. Cambridge (MA): Blackwell Scientific; 1994. p. 329-37.
341. Gupta AK, Ellis CN, Siegel MT, et al. Sulfasalazine: a potential psoriasis therapy? J Am Acad Dermatol 1989;20: 797-800.
342. Gupta AK, Ellis CN, Siegel MT, et al. Sulfasalazine improves psoriasis: a double-blind analysis. Arch Dermatol 1990;126: 487-93.
343. Feldman SR. The biology and clinical application of systemic glucocorticoids. Curr Prob Dermatol 1992;6:207-35.
344. Skinner RB Jr, Rosenberg EW, Noah PW. Antimicrobial treatment of psoriasis. Dermatol Clin 1995;13:909-13.
345. Rosenberg EW, Noah PW, Skinner RB Jr, et al. Microbial associations of 167 patients with psoriasis [discussion 75]. Acta Derm Venereol 1989;146(Suppl):72-4.
346. Rosenberg EW, Noah PW, Zanolli MD, et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis: preliminary report. J Am Acad Dermatol 1986;14: 761-4.
347. Vincent F, Ross JB, Dalton M, et al. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol 1992;26: 458-61.
348. Skinner RB Jr, Rosenberg EW, Noah PW. Psoriasis of the palms and soles is frequently associated with oropharyngcal Candida albicans. Acta Derm Venereol 1994;186(Suppl): 149-50.
349. Skinner RB Jr, Noah PW, Taylor RM, et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985;12:852-6.
350. Rosenberg EW, Noah PW. The Koebner phenomenon and the microbial basis of psoriasis. J Am Acad Dermatol 1988; 18:151-8.
351. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotation therapy. J Am Acad Dermatol 1993;28:454-9.
352. Menter MA, See JA, Amend WJ, et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference, Deer Valley, Utah, October 7-9, 1994. J Am Acad Dermatol 1996;34:315-21.
353. Morison WL. PUVA combination therapy. Photodermatol Photoimmunol Photomed 1985;2:229-36.
354. Paul BS, Momtaz K, Stern RS, et al. Combined methotrexate: ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982;7:758-62.
355. Van de Kerkhof PC, Mali JW. Methotrexate maintenance following Ingram therapy in 'difficult' psoriasis. Br J Dermatol 1982;106:623-7.
356. Tuyp E, Mackie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol 1986;14: 70-3.
357. Rosenbaum MM, Roenigk HH Jr. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate. J Am Acad Dermatol 1984;10:357-61.
358. Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol 1990;30:802-7.
359. Korstanje MJ, van Breda Vriesman CJ, Van de Staak WJ. Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol 1990;23:320-1.
360. Cratchfield CE, Lewis EJ, Zelickson BD. The effective use of topical zinc pyrithione in the treatment of psoriasis: a report of three cases. J Geriatr Dermatol 1997;5:21-4.
361. Cratchfield CE 3rd, Lewis EJ, Zelickson BD. The highly effective use of topical zinc pyrithione in the treatment of psoriasis: a case report. Dermatol Online J 1997;3.
362. Zelickson BD, Mehregan DA, Wendelschfer-Crabb G, et al. Clinical and histologic evaluation of psoriatic plaques treated with a flashlamp pulsed dye laser. J Am Acad Dermatol 1996;35:64-8.
363. Elias AN, Goodman MM, Liem WH, et al. Propylthiouracil in psoriasis: results of an open trial. J Am Acad Dermatol 1993;29:78-81.
364. Elias AN, Dangaran K, Barr RJ, et al. A controlled trial of topical propylthiouracil in the treatment of patients with psoriasis. J Am Acad Dermatol 1994;31:455-8.
365. Elias AR, Barr RJ. Low-dose oral propylthiouracil in the treatment of plaque psoriasis. Int J Dermatol 1995;34:519-20.